Renalytix AI (RNLX)

1.25
0.00(0.00%)
  • Volume:
    0
  • Day's Range:
    1.25 - 1.25
  • 52 wk Range:
    1.20 - 27.83

RNLX Overview

Prev. Close
1.23
Day's Range
1.25-1.25
Revenue
2.61M
Open
1.25
52 wk Range
1.2-27.83
EPS
-0.692
Volume
0
Market Cap
43.89M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
86,922
P/E Ratio
-1.85
Beta
1.74
1-Year Change
-93.97%
Shares Outstanding
74,891,844
Next Earnings Date
Nov 30, 2022
What is your sentiment on Renalytix AI Nas?
or
Vote to see community's results!

Renalytix AI News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Renalytix AI Company Profile

Renalytix AI Company Profile

Employees
54

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.

Read More

Analyst Price Target

Average10.00 (+700.00% Upside)
High15
Low5
Price1.25
No. of Analysts2
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell